# Effectiveness of warm acupuncture and moxibustion in the treatment of osteoarthritis: a retrospective study on clinical and molecular outcomes

**Authors:** Jie Zhou, Kun Li, Yun Yang, Liangyu Lu

PMC · DOI: 10.3389/fmed.2026.1730151 · Frontiers in Medicine · 2026-02-18

## TL;DR

This study shows that warm acupuncture with moxibustion improves joint function and reduces pain and inflammation in osteoarthritis patients.

## Contribution

The study demonstrates the molecular and clinical effects of warm acupuncture and moxibustion on osteoarthritis through a retrospective cohort design.

## Key findings

- Warm acupuncture with moxibustion improved joint function and reduced pain in osteoarthritis patients.
- The treatment decreased inflammation and normalized connexin expression levels in OA patients.
- Post-treatment connexin levels were comparable to healthy controls.

## Abstract

Osteoarthritis (OA) is a degenerative joint disease that causes pain and mobility loss in older adults. This study aimed to examine changes in connexin Cx26, Cx43, and Cx45 expression in OA patients after warm acupuncture with moxibustion.

Records of 46 OA patients treated between March 2022 and December 2024 were reviewed, along with 46 age- and sex-matched healthy controls. This was a retrospective cohort study. Clinical scores [Lysholm knee score, visual analog scale (WOMAC)] were used to assess joint function, pain, and mobility. Warm acupuncture with moxibustion was applied following a standardized protocol, targeting specific acupoints, including Dubi (ST35), Zusanli (ST36), Yinlingquan (SP9), Yanglingquan (GB34), and Heding. The intervention was administered three times per week for 8 weeks. Laboratory data on bone metabolism markers [osteoprotegerin (OPG), and bone gla protein (BGP)], inflammatory mediators [MMP-1, MMP-3, prostaglandin E2, interleukin-1β, and tumor necrosis factor-α (TNF-α)], and the mRNA expression of Cx26, Cx43, and Cx45 were analyzed.

Post-treatment, the Lysholm knee score (LKSS) increased and the VAS and WOMAC scores decreased (P < 0.05). OPG and BGP levels increased, whereas MMP-1, MMP-3, PGE2, IL-1β, and TNF-α levels decreased (P < 0.05). Cx26 expression decreased, whereas Cx43 and Cx45 expression increased (P < 0.05). Connexin levels post-treatment were comparable to those of the controls (P > 0.05).

Warm acupuncture with moxibustion improved joint function, reduced pain and inflammation, and normalized connexin expression in OA patients. The standardized treatment protocol and the retrospective cohort design provide insight into the potential clinical benefits of this approach for OA management.

## Linked entities

- **Genes:** GJB2 (gap junction protein beta 2) [NCBI Gene 2706], GJA1 (gap junction protein alpha 1) [NCBI Gene 2697], GJC1 (gap junction protein gamma 1) [NCBI Gene 10052], BTF3P11 (basic transcription factor 3 pseudogene 11) [NCBI Gene 690], BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632], MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312], MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314], IL1B (interleukin 1 beta) [NCBI Gene 3553], TNF (tumor necrosis factor) [NCBI Gene 7124]
- **Diseases:** osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, Connexin [NCBI Gene 100128922], GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, GJB2 (gap junction protein beta 2) [NCBI Gene 2706] {aka BAPS, CX26, DFNA3, DFNA3A, DFNB1, DFNB1A}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, GJB6 (gap junction protein beta 6) [NCBI Gene 10804] {aka CX30, DFNA3, DFNA3B, DFNB1B, ECTD2, ED2}, GJB1 (gap junction protein beta 1) [NCBI Gene 2705] {aka CMTX, CMTX1, CX32}, GJA4 (gap junction protein alpha 4) [NCBI Gene 2701] {aka CX37}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, TNFRSF11B (TNF receptor superfamily member 11b) [NCBI Gene 4982] {aka OCIF, OPG, PDB5, TR1}, GJB3 (gap junction protein beta 3) [NCBI Gene 2707] {aka CX31, DFNA2, DFNA2B, EKV, EKVP1}, GJA8 (gap junction protein alpha 8) [NCBI Gene 2703] {aka CAE, CAE1, CTRCT1, CX50, CZP1, MP70}, GJA5 (gap junction protein alpha 5) [NCBI Gene 2702] {aka ATFB11, CX40}, GJA3 (gap junction protein alpha 3) [NCBI Gene 2700] {aka CTRCT14, CX46, CZP3}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GJC1 (gap junction protein gamma 1) [NCBI Gene 10052] {aka CX45, GJA7}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}
- **Diseases:** fracture hyperplasia (MESH:D006965), synovitis (MESH:D013585), fever (MESH:D005334), limitations in joint movement (MESH:D045745), osteoarticular dysplasia (MESH:D014394), diabetic (MESH:D003920), malignant tumors (MESH:D009369), endocrine system disorders (MESH:D004700), cold (MESH:D000067390), cystic degeneration (MESH:D018297), mental illness (MESH:D001523), ischemia (MESH:D007511), metabolic diseases (MESH:D008659), OA (MESH:D010003), infections (MESH:D007239), claudication (MESH:D007383), cartilage degradation (MESH:D002357), burns (MESH:D002056), swelling (MESH:D004487), systemic disease (MESH:D034721), knee OA (MESH:D020370), bone defects (MESH:D001847), arthralgia (MESH:D018771), knee joint soreness (MESH:D000092443), joint injury (MESH:D000092464), abdominal pain (MESH:D015746), joint damage (MESH:D007592), rheumatoid arthritis (MESH:D001172), dyskinesia (MESH:D004409), obesity (MESH:D009765), impaired wound healing (MESH:D014947), disease (MESH:D004194), degenerative joint disease (MESH:D019636), knee pain (MESH:D046788), Yang deficiency (MESH:D016711), Inflammatory (MESH:D007249), arthritis (MESH:D001168), sclerosis (MESH:D012598), muscle spasm (MESH:D013035), joint instability (MESH:D007593), joint tenderness (MESH:D063806), mobility disorders (MESH:D014086), diarrhea (MESH:D003967), osteophytes (MESH:D054850), skin irritation (MESH:D012871), epigastric pain (MESH:D010146), stiffness (MESH:C566112), fatigue (MESH:D005221), TCM (MESH:C562377), tendon lesions (MESH:D052256)
- **Chemicals:** nitrogen (MESH:D009584), sodium hyaluronate (MESH:D006820), cAMP (MESH:D000242), inositol (MESH:D007294), Angelica dahurica (-), ATP (MESH:D000255), TRIzol (MESH:C411644), PGE2 (MESH:D015232)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12959124/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12959124/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12959124/full.md

---
Source: https://tomesphere.com/paper/PMC12959124